Once hailed as an anti-aging magic bullet, telomerase has failed to live up to the hype as it was profiled in a 1998 Los ...

Thanks to respiratory syncytial virus (RSV) shot Arexvy’s new label expansion into a slightly younger pool of adults, GSK is ...

Eisai and Biogen’s reign at the top of the Alzheimer’s disease market may be short lived. | Eisai and Biogen’s reign at the ...

AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer ...

The Biotechnology Innovation Organization, under the new leadership of CEO John Crowley, recently backed the BIOSECURE Act.

A new antitrust investigation in Italy has ensnared Novartis, Genentech, Biogen and Samsung Bioepis for allegedly colluding ...

After fessing up to wire fraud charges, a former Takeda employee will be preparing for a sentencing hearing rather than ...

With legislative efforts to combat drug shortages picking up and amid a record high numbe | A report from U.S. Pharmacopeia ...

Seven years after buying land in Des Plaines, Illinois, that housed a Salvation Army campus, German CDMO Vetter Pharma is ...

The Fierce Pharma Marketing team publishes a special report each year on the top pharmaceutical drug ad spenders. This year’s ...

Eli Lilly teased “clinically meaningful” results around the ability of its dual GLP-1/GIP med tirzepatide to curb fibrosis in ...

AbbVie is once again the top spender on pharma TV ads, narrowly beating April's winner, Rexulti. | AbbVie is once again the ...